What it does
Bristol Myers Squibb states that it operates in one segment spanning the discovery, development, licensing, manufacturing, marketing, distribution and sale of medicines for serious diseases. Its stated therapeutic focus includes oncology, hematology, immunology, cardiovascular disease and neuroscience. The filing describes research platforms that include small-molecule drugs, biologics, antibody-drug conjugates, CAR-T cell therapies and radiopharmaceutical therapeutics. Its significant products include growth-portfolio medicines such as Opdivo, Orencia, Reblozyl, Camzyos and Cobenfy, as well as legacy-portfolio products including Eliquis, Revlimid, Pomalyst/Imnovid, Sprycel and Abraxane.
Source: Bristol Myers Squibb Company Form 10-K for fiscal 2025, Item 1 — sec.gov
How it makes money
The company states that it generates revenue from selling its medicines worldwide, principally through wholesalers, distributors and specialty pharmacies, with additional sales to retailers, hospitals, clinics, government agencies and directly to patients. It also reports other revenue that includes royalties and alliance-related revenue for products not sold by its regional commercial organizations. The company promotes approved uses of its products to healthcare professionals and organizations, and it works to obtain formulary and reimbursement-plan access by providing information on product clinical profiles. It reports its business as a single operating segment.
Source: Bristol Myers Squibb Company Form 10-K for fiscal 2025, Item 1 — sec.gov
Customers and geography
The filing identifies wholesalers, distributors and specialty pharmacies as Bristol Myers Squibb’s principal customers, while retailers, hospitals, clinics and government agencies account for sales to a lesser extent. The company also sells directly to patients. Its commercial activity is worldwide, and the filing presents revenue by United States, International and Other categories. In the U.S., the company has direct-sales agreements with substantially all direct wholesaler and distributor customers to monitor inventory levels. Outside the U.S., it has more direct customers, and it contracts with distributors in some countries for services that can include logistics, regulatory and pharmacovigilance support, and sales or promotion.
Source: Bristol Myers Squibb Company Form 10-K for fiscal 2025, Item 1 — sec.gov
Competition
The company states that its markets are broad-based and highly competitive. It names other global research-based drug companies, smaller research companies with more limited therapeutic focus, and generic drug manufacturers as competitors, but the filing does not name specific competing companies. The filing lists product efficacy, safety, ease of use, price, demonstrated cost-effectiveness, marketing, labeling, customer service and new-product research and development among competitive factors. It states that its immuno-oncology products, particularly Opdivo, operate in a highly competitive marketplace. The company also describes competition from lower-priced generic products after loss of market exclusivity.
Source: Bristol Myers Squibb Company Form 10-K for fiscal 2025, Item 1 — sec.gov
Key risks
-
Increased pricing pressure and other restrictions in the U.S. and abroad continue to negatively affect revenues and profit margins.
-
The company may experience difficulties or delays in the development and commercialization of new products.
-
It could lose market exclusivity of a product earlier than expected.
-
It faces intense competition from other biopharmaceutical companies and manufacturers and expects increasing market penetration of lower-priced generic products.
-
It could experience difficulties, delays and disruptions in its supply chain and in manufacturing, distribution and sale of products.
Source: Bristol Myers Squibb Company Form 10-K for fiscal 2025, Item 1A — sec.gov
People and operations
Bristol Myers Squibb reported 32,500 employees for FY2025. The company states that it has significant manufacturing operations in the U.S., Puerto Rico, the Netherlands, Ireland and Switzerland. Its operations include marketing and sales organizations, with product marketing groups supported by sales forces responsible for selling one or more products. The filing describes specialized distribution arrangements for certain medicines: Revlimid and Pomalyst are distributed in the U.S. primarily through contracted pharmacies under mandatory risk-management programs, while Camzyos is available only through its REMS program. The filing does not state that its business is seasonal.
Source: Bristol Myers Squibb Company Form 10-K for fiscal 2025, Item 1 — sec.gov